Affordable Access

Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia.

Authors
  • Taylor, Walter R
  • Richie, Thomas L
  • Fryauff, David J
  • Ohrt, Colin
  • Picarima, Helena
  • Tang, Douglas
  • Murphy, Gerald S
  • Widjaja, Hendra
  • Braitman, David
  • Tjitra, Emiliana
  • Ganjar, Asep
  • Jones, Trevor R
  • Basri, Hasan
  • Berman, Josh
Type
Published Article
Journal
Antimicrobial agents and chemotherapy
Publication Date
Jul 01, 2003
Volume
47
Issue
7
Pages
2199–2203
Identifiers
PMID: 12821468
Source
Medline
License
Unknown

Abstract

Drug tolerability affects compliance. We evaluated the tolerability levels of azithromycin (750-mg loading dose plus 250 mg/day; n = 148 subjects), doxycycline (100 mg/day; n = 75), and placebo (n = 77) as prophylaxis against malaria in Indonesian adults over 20 weeks. Self-reported and elicited symptoms, health perception, hearing, hematology, and biochemistry were assessed. The loading dose was well tolerated. The frequencies (number per person-years [p-yr]) of all daily reported symptoms were similar in the three arms of the study: 40.2/p-yr for azithromycin, 39.7/p-yr for doxycycline, and 38.2/p-yr for placebo. Relative to those who received placebo, azithromycin recipients complained more often of heartburn (rate ratio = 10.5 [95% confidence interval, 2.8 to 88.1]), paresthesia (2.03 [1.08 to 4.24]), and mild (1.55 [1.01 to 2.48]) and severe (11.2 [1.34 to infinity ]) itching but less often of fever (0.21 [0.09 to 0.49]) and tinnitus (0.09 [0.04 to 0.21]). Azithromycin recipients showed no evidence of clinical hearing loss or hematologic, hepatic, or renal toxicity. One azithromycin recipient developed an erythematous rash. Daily azithromycin was well tolerated by these Indonesian adults during 20 weeks of treatment.

Report this publication

Statistics

Seen <100 times